MaxCyte Inc (MYE0.MU)
- Simply Wall St.
With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies MaxCyte's stock price is sensitive to their trading...
- GlobeNewswire
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells.ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell
- Insider Monkey
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript May 11, 2024 MaxCyte, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank you for standing by. Welcome to the MaxCyte First Quarter 2024 Earnings Conference Call. At […]
